Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …

ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …

Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …

Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …

Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …

Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …

Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …

Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …

Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …

Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …